Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Jeito Capital

Jeito Capital leads $67.5 million (€64.4 million[1]) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease
From Jeito Capital
Via GlobeNewswire
Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials
From Jeito Capital
Via GlobeNewswire
Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 ADCs in solid tumors
From Jeito Capital
Via GlobeNewswire
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
From Jeito Capital
Via GlobeNewswire
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion
From Jeito Capital
Via GlobeNewswire
Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases
From Jeito Capital
Via GlobeNewswire
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
From Jeito Capital
Via GlobeNewswire
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders
From Jeito Capital
Via GlobeNewswire
Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing
From Jeito Capital
Via GlobeNewswire
Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics
From Jeito Capital
Via GlobeNewswire
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
From Jeito Capital
Via GlobeNewswire
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
From Jeito Capital
Via GlobeNewswire
Jeito Capital co-leads €75 million Series B financing in SparingVision
From Jeito Capital
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.